Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Analytical Method Development: SOP for Oxidative Degradation Study Method – V 2.0

Posted on By

Analytical Method Development: SOP for Oxidative Degradation Study Method – V 2.0

Standard Operating Procedure for Oxidative Degradation Study Method in Analytical Method Development


Department Analytical Method Development
SOP No. SOP/AMD/190/2025
Supersedes SOP/AMD/190/2022
Page No. Page 1 of 14
Issue Date 19/05/2025
Effective Date 20/05/2025
Review Date 19/05/2026

1. Purpose

This SOP describes the procedure for conducting oxidative degradation studies on active pharmaceutical ingredients (APIs) and drug products to determine their susceptibility to oxidative stress.

The method is essential for developing stability-indicating analytical procedures as per ICH Q1A(R2) and Q2(R2) guidelines.

2. Scope

This SOP applies to all APIs and finished pharmaceutical dosage forms being evaluated in the Analytical Method Development (AMD) department. It includes oxidative degradation using hydrogen peroxide (H2O2) at varying concentrations and durations.

See also  Analytical Method Development: Limit Test for Chloride/Sulphate Development - V 2.0

3. Responsibilities

  • Analytical Scientist: Designs the oxidative degradation protocol and interprets results.
  • Lab Analyst: Prepares and analyzes oxidized samples and records degradation profiles.
  • QA Officer: Reviews study documentation and ensures procedural compliance.
  • Head – AMD: Approves the method and final study report for validation and regulatory filing.

4. Accountability

The Head of AMD is accountable for ensuring oxidative degradation studies are conducted with scientific rigor and documented as per regulatory expectations.

5. Procedure

5.1 Protocol Design

  1. Design a written protocol specifying:
    • Sample name, batch, and strength
    • Hydrogen peroxide concentration (3% or 10%)
    • Temperature and exposure time
    • Analytical method and detection wavelength
  2. Obtain QA and department head approvals prior to execution.

5.2 Oxidative Stress Conditions

  1. Prepare fresh 3% or 10% H2O2 solution just before use.
  2. Dissolve API/formulation in suitable solvent (methanol, water, etc.).
  3. Add equal volume of H2O2 to the solution.
  4. Incubate at room temperature (25 ± 2°C) or 40°C for 1–6 hours depending on reactivity.
See also  Analytical Method Development: SOP for Particulate Matter Testing by Light Obscuration - V 2.0

5.3 Sample Neutralization and Preparation

  1. Post-degradation, add a few drops of catalase or sodium thiosulfate to quench residual peroxide.
  2. Filter using 0.45 µm PVDF syringe filter.
  3. Dilute with mobile phase to desired concentration.
  4. Document all observations in Annexure-1: Oxidative Stress Log.

5.4 Analytical Evaluation

  1. Analyze stressed and control samples using validated HPLC/UPLC method.
  2. Record retention times, area, % assay, % degradation, and new peaks observed.
  3. Assess peak purity using PDA detection or spectral overlays.
  4. Report findings in Annexure-2: Oxidative Degradation Data Sheet.

5.5 Interpretation of Results

  1. % Degradation between 5%–20% is considered acceptable to demonstrate method sensitivity.
  2. Degradation peaks must be baseline separated from main API peak.
  3. Any co-elution or merging of degradant with API peak invalidates method specificity.

6. Abbreviations

  • API: Active Pharmaceutical Ingredient
  • HPLC: High-Performance Liquid Chromatography
  • UPLC: Ultra-Performance Liquid Chromatography
  • PDA: Photodiode Array Detector
  • SOP: Standard Operating Procedure
See also  Analytical Method Development: Structural Elucidation by NMR - V 2.0

7. Documents

  1. Oxidative Stress Log – Annexure-1
  2. Oxidative Degradation Data Sheet – Annexure-2

8. References

  • ICH Q1A(R2) – Stability Testing of New Drug Substances and Products
  • ICH Q2(R2) – Validation of Analytical Procedures
  • USP General Chapter <1225> – Validation of Compendial Procedures

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Oxidative Stress Log

Sample ID H2O2 Conc. Temp (°C) Duration (hrs) Remarks
OX-API-019 3% 25 4 No visual discoloration

Annexure-2: Oxidative Degradation Data Sheet

Sample ID Assay (%) % Degradation New Peaks (RT) Peak Purity Conclusion
OX-API-019 87.6 12.4 5.3, 6.8 Pass Oxidation observed

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Added neutralization procedure and clarified peroxide concentration range Regulatory inspection preparation
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: Regulatory Risks of Obsolete SOPs in Circulation
Next Post: Elixir Department: SOP for Operation of Recirculation Loops – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version